

Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry

Francesco Bonomi^{1,2,*}, Cosimo Bruni^{1,3,*}, Silvia Peretti^{1,2}, Rossella De Angelis⁴, Gianluigi Bajocchi⁵, Dilia Giuggioli⁶, Martina Orlandi⁶, Giovanni Zanframundo⁷, Rosario Foti⁸, Giovanna Cuomo⁹, Alarico Ariani¹⁰, Edoardo Rosato¹¹, Gemma Lepri², Francesco Girelli¹², Valeria Riccieri¹³, Elisabetta Zanatta¹⁴, Silvia Laura Bosello¹⁵, Ilaria Cavazzana¹⁶, Francesca Ingegnoli¹⁷, Maria De Santis¹⁸, Fabio Cacciapaglia^{19,20}, Giuseppe Murdaca²¹, Giuseppina Abignano²², Giorgio Pettiti²³, Alessandra Della Rossa²⁴, Maurizio Caminiti²⁵, Anna Maria Iuliano²⁶, Giovanni Ciano²⁷, Lorenzo Beretta²⁸, Gianluca Bagnato²⁹, Ennio Lubrano³⁰, Ilenia De Andres³¹, Luca Idolazzi³², Marta Saracco³³, Cecilia Agnes³⁴, Corrado Campochiaro³⁵, Edoardo Cipolletta⁴, Marco Fornaro¹⁹, Federica Lumetti⁶, Amelia Spinella⁶, Luca Magnani⁵, Giacomo De Luca³⁵, Veronica Codullo⁷, Elisa Visalli⁸, Carlo Iandoli⁹, Antonietta Gigante¹¹, Greta Pellegrino^{36,37}, Erika Pigatto³⁸, Maria Grazia Lazzaroni¹⁶, Enrico De Lorenzis¹⁵, Gianna Mennillo²², Marco Di Battista²⁴, Giuseppa Pagano-Mariano²⁵, Federica Furini³⁹, Licia Vultaggio³⁹, Simone Parisi⁴⁰, Clara Lisa Peroni⁴⁰, Gerolamo Bianchi⁴¹, Enrico Fusaro⁴⁰, Gian Domenico Sebastiani²⁶, Marcello Govoni³⁹, Salvatore D'Angelo²², Franco Cozzi³⁸, Franco Franceschini¹⁶, Serena Guiducci², Lorenzo Dagna³⁵, Andrea Doria¹⁴, Carlo Salvarani⁶, Maria Antonietta D'Agostino, Florenzo Iannone¹⁹, Clodoveo Ferri^{6,42}, Marco Matucci-Cerinic³⁵, Silvia Bellando Randone¹ on behalf of SPRING-SIR (Systemic Sclerosis PROgression INvestiGation group of the Italian Society for Rheumatology)[#].

* Both authors contributed equally

[#] All members of SPRING-SIR are listed in the authorship list.

⁺ Corresponding Author: Francesco Bonomi, Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Largo Brambilla 3, 50139, Florence, Italy. francesco.bonomi@unifi.it

Affiliations:

¹ Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy;

² Department of Internal Medicine, University Hospital Careggi, Florence, Italy;

³ Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland;

⁴ Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy;

⁵ Rheumatology Unit, S. Maria Hospital-USL, IRCCS Institute, Reggio Emilia, Italy;

⁶ University Hospital of Modena and Reggio Emilia School of Medicine, Department of Medical and Surgical Sciences for Children and Adults, Modena, Italy;

⁷ Department of Internal Medicine and Therapeutics, Università di Pavia, Italy; Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;

1
2
3⁸ Rheumatology Unit, AOU Policlinico San Marco, Catania, Italy;
4
5⁹ Department of Precision Medicine - Univeristy of Campania - Luigi Vanvitelli University, Naples,
6
7 Italy;
8
9¹⁰ Department of Medicine, Internal Medicine and Rheumatology, Azienda Ospedaliero
10
11 Universitaria di Parma, Parma, Italy;
12
13¹¹ Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy;
14
15¹² Department of Medicine, Rheumatology Unit, Ospedale GB Morgagni–L Pierantoni, Forlì, Italy;
16
17¹³ Department of Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza
18
19 University of Rome, Rome, Italy;
20
21¹⁴ Department of Rheumatology, University of Padua, Padova, Italy;
22
23¹⁵ Rheumatology Division, Catholic University of the Sacred Heart, Fondazione Policlinico
24
25 Universitario A. Gemelli- IRCCS – Rome, Italy;
26
27¹⁶ Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia; Department of
28
29 Clinical and Experimental Sciences, University of Brescia, Brescia, Italy;
30
31¹⁷ Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-
32
33 CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027,
34
35 Università degli Studi di Milano, Milan, Italy;
36
37¹⁸ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan and Research
38
39 Hospital, Milan, Italy;
40
41¹⁹ Rheumatology Unit, Department of Precision and Regenerative Medicine-Ionian Area, University
42
43 of Bari “Aldo Moro”, Bari, Italy;
44
45²⁰ Reumatology Service, “F.Miulli” General Hospital – Department of Medicine and Surgery, LUM
46
47 ‘G. De Gennaro’, Casamassima
48
49²¹ Department of Internal Medicine, University of Genoa and allergology and clinical immunology
50
51 unit, ospedale San Bartolomeo Sarzana, Italy;
52
53²² Department of Health Science, University of Basilicata. Rheumatology Unit, San Carlo Hospital,
54
55 Potenza, Italy;
56
57²³ Rheumatology Unit ASO S. Croce e Carle Hospital, Cuneo, Italy;
58
59²⁴ Department of Rheumatology, University of Pisa, Pisa, Italy;
60
²⁵ Departmental Rheumatology Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy
²⁶ Rheumatology Unit, San Camillo–Forlanini Hospital, Rome, Italy;
²⁷ Hospital of Ariano Irpino, Local Health Department, Ariano Irpino, Italy;
²⁸ Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda, Ospedale
Maggiore Policlinico di Milano, Milan, Italy;

- ²⁹ Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy;
- ³⁰ Department of Rheumatology, University of Molise, Campobasso, Italy;
- ³¹ Rheumatology Unit, Azienda Ospedaliera di Rilievo Nazionale ed Alta Specializzazione Garibaldi, Catania, Italy;
- ³² Rheumatology Unit, Department of Medicine, University of Verona, Piazzale A. L. Scuro 1, 37138, Verona, Italy;
- ³³ Rheumatology Unit, Mauriziano-Umberto I Hospital, Turin, Italy;
- ³⁴ Department of Medicine, Division of Rehabilitation, Torino, ASL TO5, Carmagnola (TO), Italy;
- ³⁵ Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy;
- ³⁶ Department of Rheumatology, IRCCS Ospedale Galeazzi- Sant' Ambrogio, Milan, Italy;
- ³⁷ Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Milan, Italy;
- ³⁸ Department of Medicine, Villa Salus Hospital, Mestre, Italy;
- ³⁹ Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-Universitaria S. Anna, Ferrara, Italy;
- ⁴⁰ Rheumatology Unit, Azienda Ospedaliera Universitaria Città Della Salute e della Scienza di Torino, Turin, Italy;
- ⁴¹ Rheumatology Unit, Department of Medical Specialities, Local Health Trust 3, Genoa, Italy;
- ⁴² Rheumatology Clinic 'Madonna dello Scoglio' Crotonei, Crotone, Italy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract.

Objectives. To describe the prevalence of gastrointestinal (GI) symptoms in systemic sclerosis (SSc) and Very Early Diagnosis of SSc (VEDOSS), identify clinical and serological features associated with GI involvement, and explore a cranio-caudal pattern of symptom distribution, using data from the Italian SPRING-SIR registry.


Methods. This cross-sectional analysis included patients fulfilling 2013 ACR/EULAR SSc or VEDOSS criteria. GI involvement was defined as symptoms in at least one GI tract segment and categorized as upper and lower. Associations between GI involvement and clinical variables were assessed using logistic and ordinal regression models, adjusting for demographics, disease characteristics, and autoantibodies.

Results. Among 1917 SSc patients, 56% had GI symptoms, associated with longer disease duration, diffuse cutaneous SSc (dcSSc), interstitial lung disease (ILD), digital ulcers (DU), telangiectasias, and tobacco exposure. Extensive GI involvement correlated with more severe disease. Ordinal regression identified female sex, dcSSc, ILD, DU, telangiectasias, tobacco exposure, and anti-centromere antibodies as variables significantly associated with more extensive GI involvement. Disease duration did not show a significant association with GI symptom extent. Among 211 VEDOSS patients, 41.2% reported GI symptoms (mostly esophageal), significantly associated with puffy fingers, and dyspnea. Among VEDOSS, puffy fingers and anti-centromere antibodies were independent predictors of presence of esophageal symptoms.

Conclusion. GI involvement in SSc is linked to more severe disease and longer disease duration. Disease duration resulted linked to the presence of GI symptoms rather than extent of GI involvement. Puffy fingers and anti-centromere antibodies may associate with presence of early esophageal symptoms in VEDOSS.

Graphical abstract

Gastrointestinal involvement in very early and established Systemic Sclerosis

**RHEUMATOLOGY**

Bonomi et al. Gastrointestinal involvement in very early and established Systemic Sclerosis: insights from the SPRING-SIR national Italian registry. *Rheumatology*.

Key messages:

- Gastrointestinal symptoms are frequent in SSc and VEDOSS, correlating with severe systemic involvement.
- In SSc, disease duration predicts onset of gastrointestinal involvement, while vascular features correlate with extent.
- In VEDOSS, puffy fingers and anti-centromere antibodies associate with early esophageal involvement.

Keywords: Systemic sclerosis; VEDOSS; Gastrointestinal involvement; Esophageal dysmotility; Autoantibodies; Disease progression

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Systemic sclerosis (SSc) is a rare, chronic, and heterogeneous systemic autoimmune rheumatic disease characterized by the combination of vascular damage, immune dysregulation, and fibrosis¹. Clinically, SSc is a multisystem disease that can affect various organ systems, with significant morbidity associated with pulmonary, cardiovascular, and gastrointestinal (GI) involvement². GI complications are common in SSc, affecting up to 90% of patients at some point during the course of the disease³. GI complications vary widely, ranging from mild symptoms such as dysphagia, gastroesophageal reflux and bloating, to more severe manifestations like gastroparesis, paralytic ileus, and intestinal pseudo-obstruction⁴. In SSc, GI involvement is not only a source of considerable discomfort but also contributes significantly to the overall disease burden, impacting patients' quality of life, vitality, and mental health, with established associations with anxiety and depression⁵, and complicating their long-term management⁶.

Despite the high prevalence, GI manifestations of SSc remain often under-recognized and undertreated, partly due to their heterogeneous nature and the reliance on subjective symptom-based assessments rather than specific diagnostic biomarkers⁷⁻⁹. Therefore, it is difficult for clinicians to accurately monitor disease progression and stratify patients based on their risk of severe GI complications. This results in suboptimal management with few targeted therapies available and a paucity of well-established treatment guidelines¹⁰.

In the management of SSc GI involvement, the challenge is represented by the uncertainties that characterize the various domains. In fact, although fibrosis and vascular abnormalities are central to disease progression, the exact mechanisms leading to GI damage are not fully understood¹¹. It is hypothesized that, over the course of SSc, GI involvement follows a cranio-caudal progression, starting from the esophagus and advancing to the intestines¹². Clinical observations and studies indicate that esophageal dysmotility may precede other GI manifestations, such as small bowel and large intestine involvement, but this hypothesis still awaits to be proved. Additionally, the variability in symptom progression over time underlines the need for a personalized approach to patient care. Distinct trajectories of GI complications have been identified in SSc patients, suggesting that while some patients experience rapid progression, others maintain relatively stable GI function¹³. These findings, along with the identification of risk factors such as female sex, smoking, and specific autoantibodies¹⁴⁻¹⁷, have identified pulmonary fibrosis and extensive cutaneous involvement¹⁵ as risk factors for more severe GI manifestations. Despite these associations, reliable biomarkers for predicting GI involvement remain elusive, highlighting the need for improved risk stratification strategies.

Identifying patients who are likely to develop severe GI complications and determining the optimal timing for screening and interventions is essential for improving outcomes¹². Therefore, our study aims to address key gaps in understanding of GI involvement in SSc by describing the prevalence of GI symptoms in established SSc and Very Early Diagnosis of SSc (VEDOSS) populations using nationwide data from the SSc Progression INvestiGation (SPRING) registry of the Italian Society of Rheumatology (SIR). Moreover, our aim was to identify potential predictors of presence and extent of GI involvement, while also testing the hypothesis of a cranio-caudal pattern of progression of GI symptoms and to investigate whether disease duration may be associated with this pattern of progression, contributing to a more accurate profiling of patients based on their individual risk factors.

Patients and Methods

We conducted a cross-sectional analysis of baseline data from patients enrolled in the SPRING-SIR registry. The SPRING-SIR registry is a prospective, multicenter cohort study that has consecutively enrolled SSc-spectrum cases since 2015, up to June 2022. This strategic, non-profit initiative is led by the Italian Society for Rheumatology (SIR) and involves 38 centers across Italy¹⁸. Patients were not selected based on disease duration or severity. Thus, the cohort includes both early and established cases. Longitudinal follow-up data were not analyzed in this study due to high numbers of loss to follow-ups and short follow-up duration. The study protocol was approved by the Ethics Committees of all participating centers following the authorization of the coordinating center (reference number OSS 15.010, AOU Careggi, Florence). All participants provided written informed consent before taking part in the study. Data collection and management were performed using Research Electronic Data Capture (REDCap), a secure web-based platform designed for supporting clinical research data. From the SPRING-SIR registry, we included both patients diagnosed with SSc who met the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)¹⁹ classification criteria for SSc and VEDOSS patients, defined as patients with Raynaud's phenomenon (RP) and at least one other VEDOSS criterion (ANA, SSc antibodies, puffy fingers or scleroderma pattern on nailfold videocapillaroscopy), but who did not meet the 2013 ACR/EULAR SSc classification criteria. Patients with missing information on GI symptoms were excluded.

In the SPRING-SIR registry, GI symptoms are differentiated into esophageal (defined as patient-reported presence of reflux or dysphagia), gastric (defined as patient-reported early satiety and vomiting), and intestinal tracts (defined as patient-reported diarrhea, bloating or constipation). "GI involvement" was defined as the presence of symptoms in at least one of these regions, while the extent of involvement was classified into two categories: "upper GI involvement" which referred to presence of esophageal or gastric symptoms (but not intestinal), and "lower GI involvement", which

included intestinal symptoms regardless of the presence of upper GI symptoms. In addition, patients were arbitrarily stratified in 5 groups according to disease duration, defined as the time from the onset of the first non-Raynaud's phenomenon sign or symptoms (≤ 3 years, >3 and ≤ 6 years, >6 and ≤ 9 years, >9 and ≤ 12 years, >12 years). Definitions of other clinical variables (e.g., ILD, scleroderma renal crisis, myositis, PAH) followed the criteria adopted in the SPRING-SIR registry, based on clinical signs, laboratory tests, imaging (e.g., HRCT for ILD), and functional assessments (e.g., PFTs, echocardiography), as detailed in the original registry publication.²⁰

Descriptive analyses were performed separately for the SSc and VEDOSS cohorts, using Chi-square or Student's T test, as appropriate, to compare patients with and without GI involvement, as well as groups with different extent of GI involvement. Fisher's test was performed, when appropriate.

Multivariable logistic regression analysis was performed to identify predictors of presence of GI involvement and to evaluate which red flags were associated to a more extensive GI disease in the SSc cohort. In the VEDOSS cohort, due to sample size issues, logistic regression analysis was performed only to identify predictors of presence of GI involvement, with a sensitivity analysis focused on esophageal symptoms. To investigate the cranio-caudal progression hypothesis, which assumes a sequential progression from no GI involvement to isolated upper GI involvement, and finally to combined upper and lower GI involvement, we performed an ordinal regression analysis. This statistical method assumes a linear, unidirectional progression between these ordered categories, without reversal to less severe states, and identifies risk factors associated with progression between consecutive steps. The model presumes that the risk conferred by each predictor remains consistent across all transitions.

All regression models considered factors such as anti-centromere antibody positivity¹⁶, female sex¹⁶, tobacco exposure¹⁶, telangiectasias^{21,22}, and digital ulcers²³ as potential predictors, as these have been previously linked to the presence or progression of GI involvement in other publications. Additionally, we explored the potential correlation with interstitial lung disease (ILD), as a connection between gastroesophageal reflux and ILD is widely recognized^{24–28}. We also included diffuse cutaneous SSc (dcSSc), based on clinical expertise and evidence from literature^{29–32} suggesting that these patients tend to exhibit more extensive GI involvement. Lastly, age and disease duration were included in the models, as it is commonly believed that GI involvement follows a cranio-caudal progression, with its extent worsening over time, although literature data are limited^{11,12}. All statistical analyses were performed using SPSS version 29.0, and a p-value of <0.05 was considered statistically significant.

Results

Prevalence and characteristics of patients with GI involvement

Out of 2178 enrolled patients, 1917 met the inclusion criteria for definite SSc cohort and 211 for the VEDOSS cohort. Fifty patients were excluded due to missing information regarding GI symptoms. The demographic and clinical characteristics of SSc patients with and without GI symptoms are detailed in Supplementary Table S1. Overall, 56% of the SSc patients reported GI symptoms at baseline visit. Patients with GI symptoms exhibited a longer disease duration (9.84 vs 7.75 years, $p < 0.001$), as well as a higher prevalence of dcSSc (23.8% vs 13.2%, $p < 0.001$) and ILD (43.5% vs 31%, $p < 0.001$), in line with poorer lung function values. Alongside these clinical features, patients with GI involvement had significantly higher frequencies of telangiectasias (68.0% vs 49.1%, $p < 0.001$), digital ulcers (25.4% vs 15.6%, $p < 0.001$), and digital pitting scars (54.2% vs 36%, $p < 0.001$), and were more frequently treated with vasoactive-vasodilating therapies.

When patients were stratified by the extent of GI involvement—from those without any GI symptoms to those with isolated upper GI manifestations, and further to those with both upper and lower GI symptoms—similar findings emerged (Table 1). Patients with combined upper and lower GI involvement had the longest disease duration (11.6 ± 9.5 years) and a markedly higher prevalence of dcSSc (28%, $p < 0.001$) and sclerodactyly (76.8%, $p < 0.001$), indicative of more aggressive fibrotic phenotype compared to cases with isolated upper or no GI involvement. Similarly, vascular abnormalities were also progressively more pronounced in groups with higher extent of GI involvement (late nailfold videocapillaroscopy pattern seen in 19.8% patients without GI symptoms, 28.1% with upper GI symptoms and 33.8% with late GI symptoms, $p < 0.001$). ILD was also increasingly more present alongside a higher GI symptom burden: with a prevalence of 47.1% in patients with both upper and lower GI involvement compared to 42.3% in those with isolated upper GI symptoms and 31% in patients without GI symptoms ($p < 0.001$).

GI involvement increases with disease duration

Looking at the prevalence of GI involvement across groups with different disease durations at the time of enrollment in the registry, we observed that the frequency of patients without GI symptoms decreased progressively—from 56.2% in those with a disease duration of less than 3 years to 37.7% in patients with more than 12 years—while the prevalence of GI symptoms correspondingly increased from 43.8% to 62.3% ($p < 0.001$). When patients were stratified by the extent of GI involvement, both the prevalence of isolated upper GI symptoms and combined upper and lower GI symptoms increased in those with longer disease duration, with a significant difference between the three groups ($p < 0.001$). Specifically, patients with isolated upper GI symptoms increased from 32.2% in those

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

with less than 3 years of disease to 41.3% in those with more than 12 years, while the prevalence of combined upper and lower GI symptoms rose from 11.6% to 21% (Figure 1).

Predicting presence and extent of GI involvement

Multivariable logistic regression identified several independent parameters associated with GI involvement (Figure 2a). Specifically, the presence of telangiectasias (OR 1.707, 95% CI 1.357–2.147, $p<0.001$), tobacco exposure (OR 1.511, 95% CI 1.186–1.925, $p<0.001$), dcSSc (OR 1.793, 95% CI 1.320–2.434, $p<0.001$), ILD (OR 1.443, 95% CI 1.142–1.823, $p=0.002$), digital ulcers (OR 1.583, 95% CI 1.182–2.120, $p=0.002$), and longer disease duration (OR 1.027, 95% CI 1.011–1.043, $p=0.001$) were all significantly associated with GI involvement.

Ordinal regression further confirmed that prolonged disease duration (OR 1.022, 95% CI 1.009–1.035, $p<0.001$) along with ILD (OR 1.488, 95% CI 1.200–1.841, $p<0.001$), dcSSc (OR 1.739, 95% CI 1.282–2.262, $p<0.001$), digital ulcers (OR 1.650, 95% CI 1.282–2.123, $p<0.001$), telangiectasias (OR 1.904, 95% CI 1.531–2.369, $p<0.001$), female sex (OR 1.654, 95% CI 1.191–2.296, $p=0.003$) and tobacco exposure (OR 1.545, 95% CI 1.243–1.919, $p<0.001$), were independently associated with a greater extent of GI involvement (Figure 2b). Specifically, these findings imply that each of these factors significantly increased the likelihood of progression from no involvement to isolated upper GI involvement, and ultimately to combined upper and lower GI involvement. Interestingly, we additionally performed an ordinal regression analysis using a four-level model: no GI symptoms, isolated esophageal involvement, combined esophageal and gastric symptoms, and full involvement of esophagus, stomach, and intestines (presented in Supplementary Table S2). This stepwise model confirmed the same set of independent predictors (longer disease duration, ILD, dcSSc, digital ulcers, telangiectasias, female sex, and tobacco exposure), reinforcing the consistency of our findings across different classifications of GI symptom extent.

Moreover, when analyzing risk factor associated with more severe disease extent (isolated upper GI symptoms vs. combined upper and lower involvement), digital ulcers (OR 1.697, 95% CI 1.191–2.415, $p=0.003$), telangiectasias (OR 1.757, 95% CI 1.211–2.551, $p=0.003$), and anti-centromere antibodies (OR 1.647, 95% CI 1.161–2.342, $p=0.005$) emerged as significant predictors, while disease duration did not reach significance in this specific analysis (OR 1.006, 95% CI 0.987–1.025, $p=0.560$) (Figure 2c).

GI involvement in VEDOSS

Of the 211 enrolled VEDOSS patients, 87 (41.2%) reported GI symptoms at baseline: 75 (35.5%) esophageal, 23 (10.9%) gastric, and 26 (12.3%) intestinal symptoms, respectively. The demographic

and clinical characteristics of patients with and without GI symptoms are detailed in Table 2. Although no statistically significant difference was observed in terms of age, sex, antibody positivity and time from Raynaud's phenomenon onset, VEDOSS patients with GI symptoms presented significantly more frequently puffy fingers (29.9% vs 15.3%, $p=0.016$), dyspnea (27.6% vs 6.5%, $p<0.001$), and sicca symptoms (40.2% vs 18.5%, $p<0.001$). No difference was found in terms of prevalence of telangiectasias, ILD and concomitant medications. In both groups, history of digital ulcers was negative.

Logistic regression identified puffy fingers as the only statistically significant predictor of presence of any GI involvement among VEDOSS patients (OR 2.174, 95% CI 1.082–4.371, $p=0.029$). When specifically focusing on esophageal symptoms, as the most prevalent type of GI involvement in this subgroup, puffy fingers were confirmed as an independent predictor (OR 2.806, 95% CI 1.346–5.849, $p=0.006$), along with anti-centromere antibodies (OR 2.075, 95% CI 1.104–3.899, $p=0.023$).

Discussion

Our study provides comprehensive insights into the intricate relationship between GI involvement and other clinical manifestations of definite SSc and VEDOSS patients, highlighting possible key predictors associated with the presence of GI symptoms. The findings highlight the substantial burden of GI symptoms in SSc (more than half of the patients in our cohort) and reveal significant associations with systemic disease severity, pulmonary and cutaneous manifestations, and increased treatment need.

Patients with GI symptoms had a longer disease duration, consistent with previous studies showing that GI involvement tends to progress alongside the SSc course^{16,33}. Disease duration was identified as an independent predictor of both upper and lower GI symptoms, with the highest prevalence observed in patients with a disease duration exceeding 12 years. Interestingly, while disease duration independently predicted the presence of both upper and lower GI symptoms, it was not associated with the progression from upper to lower GI involvement. This challenges the commonly held assumption that GI manifestations in SSc follow a cranio-caudal (upper-to-lower) progression, suggesting instead that upper and lower GI involvement may develop independently rather than representing sequential stages of a single disease process.

Our findings deepen the knowledge in GI tract involvement in SSc and complements the findings of recent literature. Our cross-sectional registry-based data provide insights into the anatomical distribution of GI symptoms and their relationship with disease duration and systemic manifestations at the time of first clinical consultation. In their elegant analysis, Perin et al. used longitudinally collected Medsger GI severity scores to capture the temporal dynamics of GI burden in terms of

severity¹³. Interestingly, patients in the “early progressive” and “early severe” GI clusters had longer disease duration at baseline compared to the “late progressive” and “stable” clusters, the latter including over 80% of their large SSc cohort. However, since the Medsger score reflects symptom severity rather than anatomical extent, patients classified as “stable” may still experience progression in terms of anatomical disease extent (e.g., from esophageal to lower GI involvement) without a marked change in severity scores. Likewise, an increase in severity of upper GI – esophageal disease may not be associated to a further disease extent to the lower, intestinal GI tract.

These methodological differences in the two studies highlight that the two approaches are not directly comparable, but rather complementary. Taken together, these perspectives reinforce the importance of identifying patients in the early phases of disease, even when symptoms are mild or subclinical, to better characterize the natural history of GI involvement and start timely therapeutic strategies aimed at preventing irreversible damage.

Our data also confirm a robust association between GI involvement and severe pulmonary manifestations, such as ILD and reduced pulmonary function (DLCO and FVC). This relationship was further supported by the independent association between ILD and GI involvement observed in the logistic regression analysis, highlighting the interplay between these organ systems in SSc. One possible explanation for these findings lies in the hypothesis that persistent microaspirations²⁴ caused by reflux may contribute to progressive interstitial lung damage. While the causal relationship remains controversial, existing literature aligns with our results^{25–27,34}, showing an association between severe esophageal dysfunction, such as absent peristalsis, and greater extent of pulmonary involvement. Additionally, it has been shown that the severity of reflux symptoms correlates with ILD progression over two years, further reinforcing the link between GI and pulmonary involvement in SSc²⁸.

Cutaneous manifestations also emerged as a clinical parameter which significantly correlates with GI involvement, in particular in dcSSc patients exhibiting a higher prevalence of GI symptoms. This association likely reflects the underlying pathophysiological mechanisms, such as widespread vascular dysfunction and fibrosis, which may contribute to both skin and GI tract involvement. Additionally, specific markers of severe skin and microvascular involvement, including digital ulcers, telangiectasias, and digital pitting scars, were significantly more common in patients with GI symptoms, suggesting that these features could serve as “red flags” for clinicians in identifying patients at higher risk for GI complications.

Furthermore, active tobacco exposure emerged as a significant predictor of GI symptoms, consistent with prior findings³⁵, highlighting the need for smoking cessation programs as part of disease management strategies.

Therapeutically, patients with GI involvement frequently received biologic DMARDs, endothelin receptor antagonists, PDE5 inhibitors, and prostanoids, reflecting the higher prevalence of systemic complications, such as diffuse ILD and vascular involvement, in this subgroup rather than a direct link to GI involvement itself. However, GI involvement plays a crucial role in therapeutic decision-making, as the potential GI side effects of therapies can significantly impact patient preferences and treatment adherence. Recent studies underscore the importance of shared decision-making in optimizing treatment strategies for SSc, integrating patient preferences regarding potential adverse events, such as GI symptoms, into therapeutic planning^{36,37}. Future research should explore how targeted therapies, including immunomodulators and vascular agents, can address both systemic and GI disease manifestations while aligning with patient needs and preferences³⁸. Additionally, a protective role of calcium channel blockers has been suggested in reducing the severity of GI symptoms¹⁶, while a potential benefit from immunosuppressive treatment has been suggested on GI manifestations observing better UCLA GIT 2.0 scores in the cohort treated with immunosuppressants³⁹.

Finally, the association between autoantibodies and GI involvement in SSc remains inconsistent, also after our analysis. For instance, anti-centromere antibodies were linked to an increased risk of severity in GI involvement¹⁶, whereas anti-topoisomerase I antibodies were associated with late progression of GI symptoms¹³, suggesting that vascular dysfunction might play a key role in the progression of GI involvement. Although anti-centromere antibodies were not associated with a clear progression pattern¹³, our data suggests that they might have a role in the onset of GI involvement. This hypothesis was further supported by our observation that anti-centromere antibodies were found to be predictors of esophageal symptoms in VEDOSS patients.

Consistent with this an early esophageal and anorectal dysfunction has been observed in VEDOSS patients⁴⁰, detecting functional abnormalities even among asymptomatic individuals. Specifically, although only 49% and 14% of patients reported esophageal and anorectal symptoms, respectively, esophageal dysfunction was observed in 25% of asymptomatic cases, and nearly all asymptomatic patients showed anorectal abnormalities⁴⁰. Our findings reinforce these observations, showing a high prevalence of GI symptoms in VEDOSS patients, particularly esophageal, which often precedes other systemic SSc manifestations. This is particularly interesting as a recent machine learning analysis of the EUSTAR-VEDOSS registry has shown that the presence of esophageal symptoms significantly increases the predictive accuracy for progression to definite SSc⁴¹. Patients with Raynaud's phenomenon, positive ANA, and esophageal symptoms had a 55% progression rate over five years, compared to 47% in those without esophageal involvement. The inclusion of esophageal symptoms alongside SSc-specific autoantibodies identified individuals with a significantly shorter time-to-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

progression, suggesting that esophageal dysfunction may serve as an additional “red flag” in risk stratification models. Furthermore, puffy fingers, a hallmark feature in the VEDOSS criteria, have been shown in previous studies as a critical 'red flag' in patients with Raynaud's phenomenon, signaling an increased risk of transitioning to SSc^{42,43}. Our findings support the notion that puffy fingers are not merely a clinical sign but also a critical marker of underlying disease progression, particularly when associated with GI symptoms. Together, these findings highlight the pathogenic potential of ACA and puffy fingers as early indicators of GI disease in SSc, and the importance of systematic early screening and longitudinal assessment of GI function in patients at risk.

Our study has some limitations: the first, its retrospective and cross-sectional design inherently limits the ability to establish causal relationships between risk factors and GI involvement and to evaluate symptom progression over time, which is not possible in the current setting due to the limited number of follow up visits and of patients developing new GI events. In fact, a prospective longitudinal study would be needed to show the progression from upper to lower GI during the disease course. Additionally, GI involvement was solely assessed based on patient-reported symptoms: this could have potentially led to an under- or over-estimation of the actual GI prevalence, considering that GI involvement can often be asymptomatic and given also the clinical challenge of differentiating SSc- and non-SSc- related causes of GI symptoms. Also, the coding of GI symptoms in the registry was based on predefined categories, without the possibility of reliably determining their underlying pathogenesis; symptoms were assigned to the most typically involved anatomical region, in line with approaches used in other registries⁴⁴. This approach, while ensuring uniformity in data collection, may have introduced a systematic misclassification bias, particularly for nonspecific symptoms such as bloating, which can originate from different segments of the GI tract. Furthermore, the coding used allowed only for the identification of the involved gastrointestinal tract, without enabling the assessment of symptom severity. Moreover, the SPRING registry did not include detailed information on GI-specific treatments, limiting insights into the therapeutic impact. Finally, we acknowledge the observational nature of the registry, including highly heterogeneous, prevalent population of SSc patients which might have contributed to a certain selection/survivor bias, as well as the limited ethnic diversity in our cohort (>98% Caucasian), which may partly impair the generalizability of our data to other geographical contexts.

Conclusions

Our data highlight that a more severe disease phenotype in SSc is strongly associated with both the presence and extent of GI involvement. Independent risk factors for GI symptoms include disease duration, dcSSc, ILD, DUs, and tobacco exposure. While disease duration is significantly linked to

the presence of GI symptoms, our data could not indirectly associate this parameter with the progression from upper to lower GI involvement, suggesting a role more in the initiation rather than the evolution of GI complications. Our findings also confirm that in the VEDOSS cohort, GI symptoms are more prevalent than other SSc-related organ involvements and manifestations, with esophageal symptoms being particularly common. We identified puffy fingers and anti-centromere antibodies as significant predictors of GI involvement in VEDOSS patient, especially esophageal symptoms, suggesting their possible role as “red flags” for progression to definite SSc. These insights emphasize the importance of early detection, personalized management, and risk stratification to alleviate the burden of GI disease and improve patient outcomes over time. Further research is essential to better understand the mechanisms driving GI manifestations and refine screening and treatment strategies accordingly.

Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Disclosure statement: C. Bruni: consulting for and congress participation support from Boehringer Ingelheim. Research grants from Foundation for Research in Rheumatology (FOREUM), Gruppo Italiano Lotta alla Scleroderma (GILS), European Scleroderma Trials and Research Group (EUSTAR), Foundation for research in Rheumatology (FOREUM), Scleroderma Clinical Trials Consortium (SCTC), Scleroderma Research Foundation (SRF), Novartis Foundation for Bio-medical Research, EMDO Foundation, Iten Kohaut Foundation, Kurt and Senta Hermann Foundation, Jubileum Foundation of Swisslife; all outside the content of the submitted work. L. Idolazzi received honoraria as an invited speaker from UCB Pharma, Eli Lilly, Johnson&Johnson, and Amgen and served on advisory boards for Eli Lilly, Johnson & Johnson, and Boehringer Ingelheim. The remaining authors declared that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability statement: Data are available for research purposes upon request.

References

1. Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. *Journal of Scleroderma and Related Disorders*. 2017 Sep 1;2(3):137–52.
2. Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. *Annals of the rheumatic diseases*. 2017 Nov 1;76(11):1897–905.
3. McMahan ZH. Gastrointestinal involvement in systemic sclerosis: an update. *Curr Opin Rheumatol*. 2019 Nov 1;31(6):561–8.
4. McMahan ZH, Khanna D. Managing gastrointestinal complications in patients with systemic sclerosis. *Curr Treat Options Gastroenterol*. 2020 Dec;18:531–44.
5. Alcala-Gonzalez LG, Guillen-Del-Castillo A, Aguilar A, Barber C, Codina C, Garcia AM, et al. Impact of gastrointestinal symptoms and psychological distress on quality of life in systemic sclerosis: a cross-sectional study. *BMJ Open*. 2024 Nov 1;14(11):e089725.
6. Hoffmann-Vold AM, Volkmann ER. Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches. *Journal of Scleroderma and Related Disorders*. 2021 Feb 1;6(1):37–43.
7. McMahan ZH, Hummers LK. Gastrointestinal involvement in systemic sclerosis: diagnosis and management. *Curr Opin Rheumatol*. 2018 Nov;30(6):533–40.
8. Affandi AJ, Radstake TRDJ, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. *Semin Immunopathol*. 2015 Sep 1;37(5):475–87.
9. Cavazzana I, Vojinovic T, Airo' P, Fredi M, Ceribelli A, Pedretti E, et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. *Clinic Rev Allerg Immunol*. 2023 Jun 1;64(3):412–30.
10. Galdo FD, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. *Annals of the Rheumatic Diseases* [Internet]. 2024 Oct 11 [cited 2024 Oct 16]; Available from: <https://ard.bmj.com/content/early/2024/10/10/ard-2024-226430>
11. Kumar S, Singh J, Rattan S, DiMarino AJ, Cohen S, Jimenez SA. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. *Aliment Pharmacol Ther*. 2017 Apr;45(7):883–98.
12. Bonomi F, Bandini G, Guiducci S, Matucci-Cerinic M, Bellando Randone S. Unveiling the hidden trajectories of gastrointestinal disease in systemic sclerosis. *Rheumatology*. 2024 Dec 26;keae658.
13. Perin J, Hughes M, Mecoli CA, Paik JJ, Gelber AC, Wigley FM, et al. Distinct clinical trajectories of gastrointestinal progression among patients with systemic sclerosis. *Rheumatology (Oxford)*. 2024 Aug 30;keae469.
14. Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, et al. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features,

and survival analysis. *J Rheumatol*. 2011 Aug;38(8):1622–30.

15. McMahan ZH, Kulkarni S, Chen J, Chen JZ, Xavier RJ, Pasricha PJ, et al. Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. *Nat Rev Rheumatol*. 2023 Mar;19(3):166–81.
16. van Leeuwen NM, Boonstra M, Fretheim H, Brunborg C, Midtvedt Ø, Garen T, et al. Gastrointestinal symptom severity and progression in systemic sclerosis. *Rheumatology*. 2022 Oct 1;61(10):4024–34.
17. Ahmed F, Maclean RH, Nihtyanova SI, Ong VH, Murray CD, Denton CP. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis. *Rheumatology (Oxford)*. 2022 Feb 2;61(2):781–6.
18. Ferri C, Giuggioli D, Guiducci S, Lumetti F, Bajocchi G, Magnani L, et al. Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of the scleroderma spectrum. *Clin Exp Rheumatol*. 2020;38 Suppl 125(3):40–7.
19. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. *Ann Rheum Dis*. 2013 Nov;72(11):1747–55.
20. De Angelis R, Ferri C, Giuggioli D, Bajocchi G, Dagna L, Bellando-Randone S, et al. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry ‘SPRING’ of the Italian Society for Rheumatology. *RMD Open*. 2023 Mar;9(1):e002890.
21. Cheah JX, Perin J, Volkmann ER, Hummers LK, Pasricha PJ, Wigley FM, et al. Slow Colonic Transit in Systemic Sclerosis: An Objective Assessment of Risk Factors and Clinical Phenotype. *Arthritis Care Res (Hoboken)*. 2023 Feb;75(2):289–98.
22. Volkmann ER, McMahan Z. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment. *Curr Opin Rheumatol*. 2022 Nov 1;34(6):328–36.
23. Bruni C, Guiducci S, Bellando-Randone S, Lepri G, Braschi F, Fiori G, et al. Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. *Rheumatology (Oxford)*. 2015 Jan;54(1):72–6.
24. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. *Semin Arthritis Rheum*. 2010 Dec;40(3):241–9.
25. Figueiredo AFSD de, Costa JF, Matos AP, Ramalho M. Esophageal Dilatation as a Predictor of Systemic Sclerosis in Patients with Interstitial Lung Disease. *Turk Thorac J*. 2021 May;22(3):231–6.
26. Salaffi F, Di Carlo M, Carotti M, Fraticelli P, Gabrielli A, Giovagnoni A. Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study. *Radiol Med*. 2018 Sep;123(9):655–63.
27. Richardson C, Agrawal R, Lee J, Almagor O, Nelson R, Varga J, et al. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. *Semin Arthritis Rheum*.

2016 Aug;46(1):109–14.

28. Volkmann ER, Tashkin DP, Leng M, Kim GHJ, Goldin J, Roth MD. Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis-Related Interstitial Lung Disease. *Arthritis Care Res (Hoboken)*. 2023 Aug;75(8):1690–7.

29. Li B, Yan J, Pu J, Tang J, Xu S, Wang X. Esophageal Dysfunction in Systemic Sclerosis: An Update. *Rheumatol Ther*. 2021 Oct 9;8(4):1535–49.

30. Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. *BMC Gastroenterology*. 2015 Feb 15;15(1):24.

31. Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, Touchene B. Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. *ISRN Rheumatol*. 2011;2011:325826.

32. Vischio J, Saeed F, Karimeddini M, Mubashir A, Feinn R, Caldito G, et al. Progression of esophageal dysmotility in systemic sclerosis. *J Rheumatol*. 2012 May;39(5):986–91.

33. Thoua NM, Bunce C, Brough G, Forbes A, Emmanuel AV, Denton CP. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. *Rheumatology (Oxford)*. 2010 Sep;49(9):1770–5.

34. Roth E, Bruni C, Petelytska L, Becker MO, Dobrota R, Jordan S, et al. Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort. *Rheumatology*. 2025 Jan 8;keaf016.

35. Luebker S, Frech TM, Assassi S, Gordon JK, Bernstein EJ, Steen VD, et al. The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation. *Clin Exp Rheumatol*. 2023 Aug;41(8):1632–8.

36. Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, et al. Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. *Rheumatology (Oxford)*. 2022 Oct 6;61(10):4035–46.

37. El Aoufy K, Bruni C, Rasero L, Matucci Cerinic M, Furst DE. Patient preferences for systemic sclerosis treatment: A descriptive study within an Italian cohort. *J Scleroderma Relat Disord*. 2021 Jun;6(2):165–9.

38. Riccieri V, Pellegrino G, Cipolletta E, Giuggioli D, Bajocchi G, Bellando-Randone S, et al. Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A case-control study from the Italian national multicenter ‘SPRING’ (Systemic Sclerosis Progression InvestiGation) Registry. *J Scleroderma Relat Disord*. 2024 Feb;9(1):38–49.

39. Stamm L, Garaiman A, Becker MO, Bruni C, Dobrota R, Elhai M, et al. Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis? *RMD Open*. 2024 Jul 24;10(3):e004333.

40. Lepri G, Guiducci S, Bellando-Randone S, Giani I, Bruni C, Blagojevic J, et al. Evidence for

oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. *Ann Rheum Dis*. 2015 Jan;74(1):124–8.

41. Di Donato S, Kakkar V, Bellando-Randone S, Matucci-Cerinic M, Del Galdo F, and EUSTAR collaborators Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis. *ACR Meeting Abstracts*. [2025 Apr 4]. Available from: <https://acrabstracts.org/abstract/machine-learning-identifies-oesophageal-symptoms-as-a-new-red-flag-for-for-very-early-diagnosis-of-systemic-sclerosis-vedoss-a-eustar-analysis/>
42. Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirják L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. *Ann Rheum Dis*. 2014 Dec;73(12):2087–93.
43. Bellando-Randone S, Galdo FD, Lepri G, Minier T, Huscher D, Furst DE, et al. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). *The Lancet Rheumatology*. 2021 Dec 1;3(12):e834–43.
44. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. *Ann Rheum Dis*. 2007 Jun;66(6):754–63.

Table 1. Comparison of demographical data and symptoms in SSc patients with different extent of GI involvement at time of enrollment in the SPRING-SIR registry.

N° of patients, 1917	GI extent			Missing (n)	p value
	No GI symptoms	Upper GI symptoms	Upper and lower GI symptoms		
	844 (45.8)	704 (38.2)	293 (15.9)	76	
Female sex, n (%)	742 (88.1)	619 (88.1)	265 (91.1)	81	0.345
Age, mean (SD)	58.1 (14.1)	59.3 (13.2)	59.5 (12.9)	78	0.147
Disease duration, mean (SD)	8.8 (7.7)	10.8 (8.6)	11.6 (9.5)	264	<0.001
Tobacco exposure, n (%)	223 (29.3)	218 (35.3)	98 (37.1)	274	0.015
Diffuse cutaneous involvement, n (%)	111 (13.2)	159 (22.6)	82 (28.0)	76	<0.001
Sclerodactyly, n (%)	506 (60.1)	539 (76.6)	225 (76.8)	78	<0.001
Puffy fingers, n (%)	442 (52.4)	358 (50.9)	142 (48.6)	78	0.531
Digital pitting scars, n (%)	303 (36.0)	377 (53.6)	174 (59.4)	78	<0.001
Digital ulcers, n (%)	132 (15.6)	164 (23.3)	96 (32.8)	76	<0.001
Telangiectasias, n (%)	414 (49.1)	455 (64.6)	217 (74.6)	78	<0.001
Calcinosis, n (%)	56 (6.7)	88 (12.5)	65 (22.2)	79	<0.001
Joints contractures, n (%)	70 (8.3)	95 (13.5)	75 (25.6)	77	<0.001
Tendon friction rubs, n (%)	40 (4.7)	62 (8.8)	51 (17.5)	77	<0.001
Arthritis, n (%)	76 (9.1)	89 (12.7)	42 (14.5)	88	0.014
Anti topoisomerase I, n (%)	286 (34.3)	239 (34.3)	100 (35.1)	100	0.970
Anti RNAPolimerase III, n (%)	12 (1.8)	10 (1.8)	6 (2.7)	461	0.685

Anti Centromere, n (%)	264 (34.1)	196 (29.9)	93 (34.2)	215	0.190
Nailfold videocapillaroscopy pattern late, n (%)	151 (19.8)	177 (28.1)	91 (33.8)	257	<0.001
Interstitial lung disease, n (%)	262 (31.0)	298 (42.3)	138 (47.1)	76	<0.001
Dyspnea, n (%)	218 (26.0)	305 (43.3)	173 (59.5)	83	<0.001
DLCO, mean (SD)	72.6 (19.9)	66.2 (19.9)	64.4 (21.5)	618	<0.001

Statistically significant results are shown in bold.

Table 2. Comparison of demographic and clinical data in VEDOSS with and without GI involvement.

Parameter	No GI symptoms	Presence of GI symptoms	Missing (n)	p value
	124 (58.8)	87 (41.2)	0	
Age, mean (SD)	52.1 (15.8)	53.7 (13.4)	0	0.428
Time from Raynaud’s phenomenon, mean, (SD)	9.19 (9.8)	10.57 (10.1)	0	0.318
Time from Raynaud’s phenomenon onset n, (%)				
<5 years	51 (41.1)	30 (34.5)		
5-10 years	32 (25.8)	22 (25.3)		
>10 years	41 (33.1)	35 (40.2)	0	0.516
Tobacco exposure n, (%)	30 (27.8)	34 (41.5)	21	0.063
Female sex n, (%)	112 (91.1)	92 (94.3)	1	0.441
ANA n, (%)	122 (98.4)	79 (96.3)	5	0.389
Anti-topoisomerase I n, (%)	14 (11.3)	12 (14.6)	5	0.524
Anti-RNAPolimerase III n, (%)	2 (1.8)	1 (1.4)	28	>0.999
Anti-Centromere n, (%)	42 (36.2)	35 (43.8)	15	0.301
Nailfold videocapillaroscopy pattern				
Early n, (%)	51 (44.3)	31 (37.8)		
Active n, (%)	22 (19.1)	17 (20.7)		
Late n, (%)	3 (2.6)	0 (0.0)	14	0.391
Sicca syndrome n, (%)	23 (18.5)	35 (40.2)	0	<0.001
Dyspnea n, (%)	8 (6.5)	24 (27.6)	1	<0.001
Puffy fingers n, (%)	19 (15.3)	26 (29.9)	0	0.016
Telangiectasias n, (%)	7 (5.6)	11 (12.6)	0	0.131
Calcinosis, n (%)	2 (1.6)	1 (1.1)	0	>0.999
Arthritis, n (%)	8 (6.5)	7 (8.1)	1	0.786
Interstitial lung disease, n (%)	1 (0.8)	4 (4.6)	0	0.162

Fisher test was used when fewer than five cases were present. Statistically significant results are shown in bold.

Figure 1. Stratification of GI extent according to disease duration, representing the time from the first non-Raynaud's phenomenon sign or symptom.

Alt text: Bar graph showing the distribution of GI involvement across different disease duration groups in SSc patients. It depicts a progressive increase in both isolated upper GI and combined upper and lower GI symptoms as disease duration lengthens, supporting a potential cranio-caudal pattern of GI symptom development.

Figure 2. Regression models of determinants of presence, extent, and distribution of GI involvement in SSc. Forest plots showing the multivariable logistic (a, c) and ordinal (b) regression models evaluating factors associated with (a) the presence of GI involvement, (b) the extent of GI involvement (increase in number of affected GI segments), and (c) the pattern of GI involvement (upper GI vs combined upper-and-lower GI involvement) in patients with SSc. The plot displays odds ratios (ORs) and 95% confidence intervals (CIs) for each covariate included in the model. All variables included in the models were categorical, except for age and disease duration (years).

Alt text: Three forest plots (panels A, B, and C) summarizing multivariable regression analyses in SSc patients. Panel A shows factors associated with presence of GI symptoms; panel B presents predictors of increasing GI involvement extent; panel C displays variables linked to progression from upper to combined upper and lower GI symptoms. Odds ratios with 95% confidence intervals are reported for each covariate.

